FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Congresses as Topic Fluorodeoxyglucose F18 Humans Immunotherapy Neoplasms / diagnostic imaging Positron Emission Tomography Computed Tomography / methods Practice Guidelines as Topic Radiopharmaceuticals Treatment Outcome
Hyperprogression Immune checkpoint inhibitors Immune-related side effects Immunotherapy Pseudoprogression Therapy response

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
01 2019
Historique:
received: 29 07 2018
accepted: 17 09 2018
pubmed: 7 10 2018
medline: 21 5 2019
entrez: 7 10 2018
Statut: ppublish

Résumé

This paper follows the immunotherapy symposium held during the European Association of Nuclear Medicine (EANM) 2017 Annual Congress. The biological basis of the immune checkpoint inhibitors and the drugs most frequently used for the treatment of solid tumours are reviewed. The issues of pseudoprogression (frequency, timeline), hyperprogression and immune-related side effects are discussed, as well as their implications for patient management. A review of the recent literature on the use of FDG PET for assessment of immunotherapy is presented, and recommendations are provided for assessing tumour response and reporting immune-related side effects with FDG PET based on published data and experts' experience. Representative clinical cases are also discussed.

Identifiants

DOI: 10.1007/s00259-018-4171-4 PMID: 30291373 PMC: PMC6267687
pubmed: 30291373
doi: 10.1007/s00259-018-4171-4
pii: 10.1007/s00259-018-4171-4
pmc: PMC6267687
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

238-250

Références

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61
pubmed: 27251642
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383
pubmed: 29124281
ESMO Open. 2018 Jan 13;3(1):e000278
pubmed: 29387476
Clin Cancer Res. 2017 Apr 15;23(8):1879-1881
pubmed: 28258060
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):17-31
pubmed: 28623376
Cancer Med. 2017 Nov;6(11):2552-2561
pubmed: 28980429
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1072-1075
pubmed: 29532102
J Thorac Oncol. 2018 Nov;13(11):1733-1742
pubmed: 29775807
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325
pubmed: 28815334
J Nucl Med. 2017 Sep;58(9):1421-1428
pubmed: 28360208
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):41-54
pubmed: 28396911
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296
pubmed: 29478079
EJNMMI Res. 2017 Dec;7(1):30
pubmed: 28361349
Pigment Cell Melanoma Res. 2016 Sep;29(5):572-7
pubmed: 27333363
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Clin Cancer Res. 2016 Sep 15;22(18):4550-5
pubmed: 27435397
Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2324-2335
pubmed: 27325312
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):133-40
pubmed: 23064544
Acad Radiol. 2017 Jan;24(1):111-115
pubmed: 27818005
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Clin Cancer Res. 2018 Jan 15;24(2):407-419
pubmed: 29074606
Clin Cancer Res. 2018 Jan 15;24(2):259-265
pubmed: 28751442
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Immunother Cancer. 2016 Sep 20;4:58
pubmed: 27660712
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96
pubmed: 25359635
Ann Oncol. 2017 Jul 1;28(7):1605-1611
pubmed: 28419181
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66
pubmed: 28828507
Invest New Drugs. 2018 Aug;36(4):638-646
pubmed: 29159766
World J Surg Oncol. 2016 Sep 05;14(1):238
pubmed: 27595749
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65
pubmed: 24029602
EJNMMI Res. 2016 Dec;6(1):61
pubmed: 27473846
J Surg Res. 2011 Nov;171(1):1-5
pubmed: 21571304
JAMA Oncol. 2016 Oct 1;2(10):1346-1353
pubmed: 27367787
J Clin Oncol. 2016 May 1;34(13):1510-7
pubmed: 26951310
Clin Nucl Med. 2018 Feb;43(2):114-116
pubmed: 29261621

Auteurs

Nicolas Aide (N)

Nuclear Medicine Department, Caen University Hospital, Caen, France. aide-n@chu-caen.fr.
Normandie University, Caen, France. aide-n@chu-caen.fr.
INSERM 1086 ANTICIPE, Normandie University, Caen, France. aide-n@chu-caen.fr.
EANM Oncology Committee, Vienna, Austria. aide-n@chu-caen.fr.
ORCID: 0000-0001-9207-0847

Rodney J Hicks (RJ)

Centre for Molecular Imaging, Department of Cancer Imaging, Peter MacCallum Cancer, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Christophe Le Tourneau (C)

Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.
INSERM U900 Research Unit, Saint-Cloud, France.

Stéphanie Lheureux (S)

Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.

Stefano Fanti (S)

EANM Oncology Committee, Vienna, Austria.
Nuclear Medicine, Policlinico S. Orsola, Università di Bologna, Bologna, Italy.

Egesta Lopci (E)

EANM Oncology Committee, Vienna, Austria.
Nuclear Medicine Department, Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Organisations et économie des soins de santé › Organismes › Congrès comme sujet › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Glucides › Désoses › Désoxyglucose › Fluorodésoxyglucose F18 › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Tumeurs › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Assurance de la qualité des soins de santé › Recommandations comme sujet › Guides de bonnes pratiques cliniques comme sujet › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › FDG PET/CT for assessing tumour response to...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › FDG PET/CT for assessing tumour response to...